Based on data collected, the combination appeared to be poorly tolearated.

This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.

Inclusion Criteria:

• Signed Informed Consent Form
• Histologically or cytologically confirmed adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease
• Age ≥ 18 years
• Adequate left ventricular function at study entry, defined as an Left Ventricular Ejection Fraction (LVEF) > 50% by either Multi Gated Acquisition(MUGA) scan or Electrocardiogram (ECHO)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria:

• Unknown HER2 status or known HER2-positive status
• Prior chemotherapy for locally recurrent or metastatic disease
• Prior hormonal therapy within 2 weeks prior to Day 1
• Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1
• Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1
• For patients who have received recent radiotherapy, ongoing Grade ≥ 3 acute toxicity
• Patients with brain metastasis on full dose anticoagulation therapy
• Life expectancy of < 12 weeks
• Current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study
• Inadequate organ function within 28 days prior to Day 1
• Untreated abnormal thyroid function tests
• Uncontrolled serious medical or psychiatric illness
• Active infection requiring IV antibiotics at enrollment or randomization
• History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
• Inadequately controlled hypertension
• Prior history of hypertensive crisis or hypertensive encephalopathy
• New York Heart Association (NYHA) Class II or greater CHF
• History of myocardial infarction or unstable angina within 12 months prior to Day 1
• History of stroke or transient ischemic attack within 12 months prior to Day 1
• Known central nervous system (CNS) disease except for treated brain metastasis
• Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1
• History of hemoptysis within 1 month prior to Day 1
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
• History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
• Serious, non-healing wound, active ulcer, or untreated bone fracture
• Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
• Known hypersensitivity to any component of bevacizumab or sunitinib
• Pregnancy (positive pregnancy test) or lactation

Based on the early safety results from this study, further recruitment and treatment was halted. Insufficient efficacy data were available to perform all protocol-specified analyses and limited the interpretation of the analyses performed.